CXCL9 and neoplasm: An alternative option, suggested herein is the “chemokine-based approach” of using CXCL10 and CXCL9 based therapies to enhance the activity of effector T cells that would then be recruited to the tumor site, possibly combined with selective elimination (depletion) of Tregs via anti CCR4 or CCR8 mAbs.